As previously reported, Scotiabank upgraded Beam Therapeutics (BEAM) to Outperform from Sector Perform with a price target of $40, up from $25, following positive data from part A of the Phase 1/2 trial of BEAM-302 in alpha-1 antitrypsin deficiency. The firm thinks the data were “a clear win for Beam in AATD,” which it views as “an underappreciated market opportunity,” the analyst told investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM:
- Cathie Wood’s ARK Investment buys 485K shares of Beam Therapeutics today
- JonesResearch upgrades Beam Therapeutics to Buy on de-risking data
- Beam Therapeutics upgraded to Buy from Hold at JonesResearch
- Beam data ‘encouraging,’ support continuation of trial, says H.C. Wainwright
- Promising Phase 1/2 Trial Results for Beam Therapeutics’ BEAM-302 Bolster Confidence and Support $80 Price Target